

ICTHIOVAC VR/PD, EMULSION FOR INJECTION FOR SEA BASS

Authorised

- Photobacterium damsela, subsp. piscicida, strain DI21, Inactivated
- Vibrio anguillarum, serotype O1, Inactivated
- Vibrio anguillarum, serotype O2b, Inactivated
- Vibrio anguillarum, serotype O2a, Inactivated

Product identification

Medicine name:

ICTHIOVAC VR/PD, EMULSION FOR INJECTION FOR SEA BASS

ICTHIOVAC VR/PD, ενέσιμο γαλάκτωμα για λαβράκι

Active substance:

Photobacterium damsela, subsp. piscicida, strain DI21, Inactivated

Vibrio anguillarum, serotype O1, Inactivated

Vibrio anguillarum, serotype O2b, Inactivated

Vibrio anguillarum, serotype O2a, Inactivated

Target species:

Seabass

Route of administration:

Intraperitoneal use

Product details

Active substance and strength:

Photobacterium damsela, subsp. piscicida, strain DI21, Inactivated

60.00 Relative Percentage Survival / 1.00 Dose

Vibrio anguillarum, serotype O1, Inactivated

75.00 Relative Percentage Survival / 1.00 Dose

Vibrio anguillarum, serotype O2b, Inactivated

75.00 Relative Percentage Survival / 1.00 Dose

Vibrio anguillarum, serotype O2a, Inactivated

75.00 Relative Percentage Survival / 1.00 Dose

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intraperitoneal use:

-

Seabass

- Fish meat. 0 degree day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI10X

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Cyprus

Package description:

500 ml bottle

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Laboratorios Hipra S.A.

Marketing authorisation date:

23/01/2023

Manufacturing sites for batch release:

Laboratorios Hipra S.A.

Responsible authority:

Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment

Authorisation number:

CY00935V

Date of authorisation status change:

23/01/2023

Reference member state:

France

Procedure number:

FR/V/0314/001

Concerned member states:

Croatia Cyprus Greece Italy Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 21/03/2023

[Download](#)